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Abstract
Unique features of immunity early in life include a distinct immune system particularly reliant on
innate immunity, with weak T helper (Th)1-polarizing immune responses, and impaired responses
to certain vaccines leading to a heightened susceptibility to infection. To these important aspects,
we now add an increasingly appreciated concept that the innate immune system displays
epigenetic memory of an earlier infection or vaccination, a phenomenon that has been named
“trained immunity”. Exposure of neonatal leukocytes in vitro or neonatal animals or humans in
vivo to specific innate immune stimuli results in an altered innate immune set point. Given the
particular importance of innate immunity early in life, trained immunity to early life infection and/
or immunization may play an important role in modulating both acute and chronic diseases.
Introduction
Immune responses consist of a complex system of cellular and humoral components that
recognize self from non-self, eliminate the latter, thereby realizing a crucial function of
neutralization of invading pathogenic microorganisms. These defense mechanisms are
essential for the survival and perpetuation of all multicellular organisms. The adaptation of
immune responses to a previously encountered infection, in order to respond with an
increased efficacy upon reinfection, gives a distinct evolutionary advantage to the host. In
humans, this function is fulfilled by specific immune responses such as the production of
antibodies (Abs) or the generation of T-cell clones specific towards a particular pathogen.
These responses are also known as adaptive immunity, because they occur as an adaptation
to infection by that pathogen. Adaptive immunity often confers lifelong protection to
reinfection with the same pathogen through the rapid clonal expansion of memory T- and/or
B-cells that induce a rapid and effective response (1).
Importantly, specific immune responses during a primary infection require several days and
up to two weeks to develop an effective antimicrobial effect. The host defense during these
first days of infection is assured by innate immunity. In contrast to T- and B-cells, the cells
of the innate immune system such as granulocytes, macrophages or natural killer (NK) cells
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tare immediately available to fight efficiently and kill a broad range of pathogens, but it has
been thought that they do not confer specificity or immunological memory to the innate host
defense.
Remarkably, the last few years of research have dramatically changed the dogma of innate
immunity being “non-specific”. Indeed, the different classes of pattern recognition receptors
(PRRs) such as the Toll-like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs), and RIG-I helicases present
on leukocytes surfaces are responsible for the semi-specific activation of cells of the innate
immune system through the specific recognition of pathogen-associated molecular patterns
(PAMPs) of pathogenic microorganisms (2). Moreover, in addition to providing early
defense against infections, the innate immune response plays an essential role in triggering
and driving the acquired immune system to respond effectively to infection (3,4). Moreover,
the dogma of innate immunity lacking memory has also started to be questioned (5). Several
studies during the last decades showed enhanced immune responses upon reinfection in
invertebrates lacking adaptive immunity, such as cockroaches (6), shrimps (7), or mealworm
beetles (8). Interestingly, invertebrates also demonstrated enhanced secondary responses (9)
and transmission of protection to offspring (10). Recently, Witteveldt et al. showed that such
innate immune memory might even be used for the vaccination of invertebrates (11).
The adaptive characteristics of innate immunity, enabling it to respond with an enhanced
efficiency during a reinfection, are evident in vertebrates as well. Enhanced heterologous
(often also referred to as “non-specific”) innate immune protection can be mediated by
epigenetic reprogramming of innate immune cells and has been called trained immunity
(12). The discovery of trained immunity may change our understanding of the scope and
nature of immunological responses.
Summary of current evidence for the Trained Immunity phenomenon
Evidence for trained immunity has been found in plants, invertebrates (e.g., insects) and,
more recently, mammals (see Table 1). Somatic rearrangement of immunological receptors
is used by vertebrates to induce adaptive immune responses (13), while alternative splicing
of pattern-recognition genes is employed by the host defense of invertebrates to confer
adaptation to infection (14). For example, Anopheles gambiae mosquitoes use alternative
splicing of the immunoglobulin (Ig)-domain coding gene “Down syndrome cell adhesion
molecule” (Dscam) to produce a highly diverse set of >31,000 potential alternative splice
forms, which enable specific recognition and protection against bacteria and parasites (15).
Thus, both somatic rearrangement and alternative splicing result in a receptor repertoire that
is sufficiently diverse to discriminate between broad varieties of different pathogens, and
provide adaptive functions to the immune system.
In addition to the mechanisms that lead to a broad panel of pathogen-recognition receptors, a
second type of adaptive immune response has been recently described, in which functional
reprogramming of innate immune cells induces an increased response to a secondary
infection. The function of the prototypic innate immune NK cells can be enhanced by a
primary viral infection, leading to protection against reinfection with viral pathogens
(16-18). Infection of mice with cytomegalovirus induced proliferation of NK cells bearing
the virus-specific Ly49H receptor. After a contraction phase at the end of the infection, these
NK cells reside in lymphoid organs for several months, and can rapidly degranulate and
produce cytokines upon viral reinfection (16). In addition, after hapten sensitization, long-
lived NK cells are responsible for the contact hypersensitivity response, independent of B
and T lymphocytes (19). Moreover, memory NK-cells can also develop adaptive immunity
to structurally diverse antigens, an activity that requires the chemokine receptor CXCR6
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t(20). Overall, memory is increasingly considered an important characteristic of NK-cell
responses.
In addition to NK cells, monocytes/macrophages also display adaptive characteristics.
Multiple murine studies have demonstrated that immunization with the anti-tuberculosis
vaccine Bacille Calmette-Guérin (BCG) protects not only against mycobacteria, but also
against infections with Listeria monocytogenes, Salmonella typhinirium, Staphylococcus
aureus (S. aureus), Candida albicans (C. albicans) or Schistosoma mansoni (21-24).
Interestingly, T-cell-independent mechanisms mediated by activated tissue macrophages
contribute to this protection (21,23,24). In addition, in children in West Africa, BCG
vaccination has been shown to confer heterologous beneficial effects with decreased
morbidity due to infections other than tuberculosis, and decreased overall mortality (25,26).
As the protection against other infections reported in these studies is heterologous (“non-
specific”), it is unlikely that a specific adaptive immune response is the protective
mechanism responsible. Indeed, it has been proposed that epigenetic reprogramming of
monocytes, based of modulation of histone methylation profiles, leads to an enhanced
function of monocytes and heterologous (“non-specific”) protection to infections induced by
BCG vaccination (27).
In addition to BCG vaccination, other specific challenges with live, attenuated agents have
produced heterologous responses. After injection of an attenuated non-germinative strain of
C. albicans, mice were protected not only against a virulent C. albicans strain, but also
against the Gram-positive bacterium S. aureus (28). Such protection is also induced in
athymic mice, indicative of a T-cell-independent mechanism (29). Protection against
reinfection is dependent on typical innate immune host response mechanisms such as
macrophages (28) and the production of pro-inflammatory cytokines (30). The molecular
mechanism of this protection is mediated by the dectin-1/Raf-1 pathway activated by β–
glucans on the cells wall of Candida, leading to a “primed” epigenetic profile based on
specific hypermethylation of histones (31). Thus, epigenetic reprogramming of monocytes is
a key novel feature of innate immune memory, (trained immunity), and is likely to be of
general importance after certain infections or immunizations.
Evidence that Trained immunity occurs in early life
Several in vitro studies suggest that the innate immune system has memory features in early
life, indeed right from birth. Stimulation of human newborn cord blood mononuclear cells in
vitro, for example with Staphylococcus epidermidis, enhances expression of a variety of
PRRs including TLRs, providing a potential mechanistic basis for greater innate immune
responses to subsequent challenges (32).
Both murine and human in vivo studies have indicated that stimulation of the neonatal innate
immune system can alter the set point of innate immunity such that responses to subsequent
stimuli are altered. Intra-peritoneal administration of TLR agonists (TLRAs) to newborn
mice enhance subsequent cytokine- and phagocyte-based responses to bacterial infection
with associated improvement in survival from polymicrobial sepsis induced by intra-
peritoneal injection of a cecal slurry (33). Of note, bloodstream infection in critically ill
preterm human newborns is associated with enhancement of pathogen-specific mononuclear
cell PRR expression in the setting of Gram-positive bacteremia (TLR2, MyD88) and Gram-
negative bacteremia (TLR4, MD-2, and MyD88) (34). A novel newborn murine model of
intravenous infection with S. epidermidis in the first 24 hours of life confirms selective
TLR2 up-regulation in liver mRNA (35). These observations suggest that the neonatal innate
immune system can remember previous activation such that responses to subsequent
microbial challenge are altered.
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tFurther evidence that early life trained immunity could be clinically relevant in vivo is
provided by a recent study indicating that histologic chorioamnionitis, known to be
associated with increased TLR expression in the chorioamniotic membranes (36), is
associated with a reduced risk of late-onset bacterial sepsis, including a lower risk of S.
epidermidis bacteremia (37). Along these lines, among the smallest, most premature infants,
early onset sepsis (EOS; i.e., that within the first 72 hours of life), is associated with a
diminished risk of late onset sepsis (LOS; i.e., that occurring after 72 hours of life) (38). As
EOS and LOS can be caused by distinct bacteria, this clinical observation raises the
possibility that innate immune engagement during EOS enhances innate immune responses
such that the risk of LOS is diminished.
Immunization of human newborns may also trigger trained immunity. A key approach to
boost vaccine immunogenicity in functionally immunocompromised individuals, such as the
very young and the elderly, is the addition of adjuvants. The self-adjuvanted BCG vaccine,
live attenuated Mycobacterium bovis, activates multiple TLRs and NOD2, triggers trained
immunity (27, 39) and is associated with reduced all cause mortality, largely due to
infections other than tuberculosis, in the first month of life (40).
Implications
Basic research/immunology
In this review we have raised the question of whether the current dogma that innate
immunity lacks memory characteristics can still be supported. We have provided an
overview of a growing body of literature that strongly suggests that innate immune
responses have adaptive characteristics. This emerging concept of mechanisms that enable
innate immune memory through trained immunity has several crucial implications. Firstly,
the discovery of trained immunity broadens the perspective through which we understand
host defense to infection. While immune memory has been considered until now as
exclusively mediated by specific T/B-cell responses, the theory of trained immunity posits
that that innate immune responses can adapt as well, strengthening, for example, broad NK-,
monocyte- and macrophage-based defense in response to prior infection.
Of note, classical immune memory and trained immunity also differ in fundamental ways.
One crucial aspect is that of molecular mechanisms employed: somatic rearrangement vs.
epigenetic reprogramming, as detailed above. Another key aspect concerns the specificity of
trained immunity. While some studies in invertebrates show specificity in protection against
certain pathogens or rejection during transplantation models, most studies in plants and
insects reveal heterologous (“non-specific”) effects in which the initial infection protects
against a larger array of secondary infections. The protection observed during trained
immunity in mammals also suggests that immunological memory of innate immune
responses is broad and not limited to a single category of pathogens, and is thus
fundamentally different from the classical adaptive immunological memory. It is tempting to
speculate that in mammals the specificity of trained immunity was lost in evolution, as its
biological relevance diminished, when adaptive immunity conferred the specificity needed
during reinfection. The description of adaptive responses within innate immunity will likely
lead to important novel insights in the mechanisms of immunomodulation on the one hand,
and in defining novel (and more effective) vaccination strategies on the other hand.
Translational studies
Trained immunity has important implications for development of novel therapeutic
modalities:
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ti. “Stand alone” immunomodulators. Molecules that activate the innate immune system via
engagement of PRRs can enhance host defense against a range of microbes. Future studies
will likely assess the potential of stand-alone PRR agonists, such as TLRAs, to boost host
defense against a range of pathogens. For example, pre-treatment with TLRAs can enhance
defense against polymicrobial sepsis in newborn mice (33). Of note, imiquimod, a TLR7A
that activates interferon-α secretion from plasmacytoid dendritic cells (pDCs) is FDA-
approved as a topical antiviral against human papilloma virus (warts) and has also been
studied off-label for treatment of mulluscipox (41). A rapidly growing number of novel
TLRAs have been identified and their activity differs with age (42) such that trained
immunity effects may be age-specific. The recent recognition of trained immunity may
inform future studies of TLRAs to boost host defense in vulnerable populations and
potentially also reduce the risks of allergy and asthma, for example via balancing Th2/Th1
polarization in accordance with the hygiene hypothesis (43).
ii. Heterologous effects of currently administered vaccines. Vaccines vary in their ability to
engage the innate immune system. For example, Alum, the most commonly used vaccine
adjuvant, may exert its adjuvant activity via a range of mechanisms, including activation of
the inflammasome and release of danger-associated molecular pattern molecules (44,45). Of
note, a birth dose of Alum-adjuvanted pneumococcal conjugate vaccine was associated with
subsequent Th2-polarization of TLRA-induced mononuclear cell cytokine responses in vitro
(46), suggesting that Alum adjuvant may trigger long-term (i.e., at least several months-
long) Th2-polarized immunity. While Th2 responses may be triggered in a distinct manner
from the aforementioned NK-/monocyte-based trained immunity, they do suggest
polarization of antigen-presenting cell function through imprinting, likely reflecting
epigenetic modulation similar to that contributing to trained immunity. Several studies
suggest that BCG may alter responses to other immunizations. For example, as compared to
infants who did not receive BCG, BCG-immunized infants have demonstrated higher
concentrations of anti-pneumococcal polysaccharide IgGs (significantly so for serotype 9V
and 18C) and of anti-Haemophilus influenzae type b IgG and anti-tetanus toxoid IgG (47).
In contrast, titers of anti-HBs IgG were lower in the BCG-immunized group than the non-
BCG-immunized group.
iii. Development of novel adjuvanted vaccine formulations. Beneficial heterologous effects
have been described for live vaccines such as BCG and measles virus vaccine (48). In this
context, future vaccine development and clinical trials should take into account not only
pathogen-specific immunity, but possibly heterologous immunomodulatory effects, some of
which may be mediated by trained immunity. Ideally, novel vaccine formulations may be
developed that not only induce pathogen-specific immunity but also have heterologous
innate immune-enhancing effects that may reduce the risk of other unrelated infections and/
or reduce the risk of allergy and atopy (43).
In conclusion, innate immunity expresses a memory function that underlies broad
heterologous immunity to antigenically diverse pathogens. Mechanisms underlying trained
immunity include epigenetic reprogramming of monocytes and macrophages, and possible
NK-cells. Much remains to learned about both the immunologic mechanisms underlying
trained immunity and the potential of innate immune memory to elicit broad beneficial
effects from select “stand alone” immune response modifiers to novel adjuvanted vaccine
formulations.
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Table 1
Studies demonstrating the presence of memory characteristics of innate immunity in plants, invertebrates and
mammals
Organism Infection type Biological effect Specificity Mechanism
Plants – “systemic acquired resistance”
Plants (refs. 49-53) Viruses, bacteria, fungi Protection against reinfection Variable Salicylic acid Epigenetic mechanisms
Non-vertebrates - Insects
Beetle (ref.8) LPS, or bacterial
prechallenge
Protection against reinfection - Transgenerational priming
Drosophila (ref.54) S. pneumonia
B. bassiana
S. marcescens
Protection + Serine protease CG33462
Anopheles gambiae (ref.55) Midgut flora Protection against Plasmodium + Toll-dependent haematocyte-differentiation factor
Mammals “trained immunity”
Mice (refs. 28,29,31) C. albicans BCG Protection against candidiasis - Monocyte epigenetic reprogramming
Mice (ref.16, 20) Murine CMV
Hypersensitization
NK-dependent + Ly49+ NK cells
Hepatic CXCR6+
NK cells
Humans (ref.27) BCG vaccination Protection against non-related
infections
- Monocyte reprogramming
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